Engineering Drugs for Personalized Medicines, Plexxikon has earned a reputation as a leader in targeted drug discovery and translational, personalized medicine.
Investors 1
| Date | Name | Website |
| - | Lightstone... | lightstone... |
Mentions in press and media 12
| Date | Title | Description |
| 26.11.2024 | Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology | Westford, USA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the global personalized medicines market size will reach a value of USD 1352.81 Billion by 2031, with a CAGR of 11.40% during the forecast period (2024-2031). The perso... |
| 25.04.2012 | Takeda, Furiex await FDA approval decision on diabetes drug Nesina | Today we might glimpse the U.S. Food and Drug Administration’s thoughts on approving new type 2 diabetes drugs in a post-Avandia world. Nesina, a Takeda Pharmaceutical (TYO:4502) compound licensed from Furiex Pharmaceuticals (NASDAQ:FURX), ... |
| 02.04.2012 | What venture capitalists look for in personalized medicine investments | “Because they can offer the right product, they can take away unnecessary costs,” Kocher said. “And in healthcare, that’s what we really need to do.” Personalized medicine will help doctors determine what to treat, how to treat and how much... |
| 07.10.2011 | Plexxikon’s Glaub: personalized medicine is ‘the wave of the future’ | Zelboraf was discovered through Plexxikon’s proprietary drug-discovery platform that develops families of protein targets. The technology allows researchers to see the way a compound binds to a particular target. That information guides Ple... |
| 11.08.2011 | Life sciences venture funding picks up in Q2 on increased exits | One bright spot in the second quarter: Average deal size increased to a mighty $10.1 million, the fourth-highest quarterly average in the last 16 years and largest since the fourth quarter of 2000. That was a 23 percent jump over both the p... |
| 13.04.2011 | RTP venture capital climate improved in Q1 but biotechs still clamor for cash | Promoted Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recov... |
| 08.01.2009 | Plexxikon teams up with Roche, eyes $335M to fight kidney disease | Pharmaceutical company Plexxikon has joined forces with health care giant Roche for at least $60 million to develop a treatment for polycystic kidney disease, commonly called PKD. Under the terms of the deal, Roche will have full global rig... |
| - | Life sciences venture funding picks up in Q2 on increased exits | Life sciences venture capital investment in the second quarter jumped 37 percent over the prior quarter on increased exit activity, according to a new report. Life sciences companies raised $2.1 million in the quarter in 206 deals. Deal vol... |
| - | What venture capitalists look for in personalized medicine investments | Companies like Starbucks (NASDAQ:SBUX), Amazon.com (NASDAQ:AMZN) and Apple (NASDAQ:AAPL) aren’t healthcare companies, but one venture capitalist believes their example can guide personalized medicine. Bob Kocher, a partner at venture capita... |
| - | Takeda, Furiex await FDA approval decision on diabetes drug Nesina | Today we might glimpse the U.S. Food and Drug Administration’s thoughts on approving new type 2 diabetes drugs in a post-Avandia world. Nesina, a Takeda Pharmaceutical (TYO:4502) compound licensed from Furiex Pharmaceuticals (NASDAQ:FURX), ... |
Show more